Aditxt (ADTX) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 12, 2020
Document Information Line Items
Entity Registrant Name	Aditx Therapeutics, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		6,978,014
Amendment Flag	false
Entity Central Index Key	0001726711
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-38561
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 49,925	$ 4,090
Prepaid expenses	25,083
TOTAL CURRENT ASSETS	75,008	4,090
Deferred offering costs	542,581	119,442
TOTAL ASSETS	617,589	123,532
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,268,581	1,847,458
Accrued compensation to related parties	1,220,629	962,651
Notes payable - related party	10,000	10,000
Notes payable, net of discount	830,600	155,600
TOTAL CURRENT LIABILITIES	4,329,810	2,975,709
TOTAL LIABILITIES	4,329,810	2,975,709
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 3,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value, 27,000,000 shares authorized, 4,069,125 and 3,915,900 shares issued and 3,968,323 and 3,821,088 shares outstanding	4,069	3,916
Treasury stock, 100,803 and 94,813 shares, respectively	(201,605)	(189,625)
Additional paid-in capital	9,938,946	9,063,483
Accumulated deficit	(13,453,631)	(11,729,951)
TOTAL STOCKHOLDERS' DEFICIT	(3,712,221)	(2,852,177)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 617,589	$ 123,532

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	27,000,000	27,000,000
Common stock, shares issued	4,069,115	3,915,900
Common stock, shares outstanding	3,968,312	3,821,087
Treasury stock	100,803	94,813

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
OPERATING EXPENSES
General and administrative expenses, includes $160,329, $2,098,759, $689,766 and $2,822,367 in stock-based compensation	$ 367,338	$ 2,511,438	$ 1,223,765	$ 3,711,221
Research and development, includes $0, $0, $0 and $0 in stock-based compensation	28,294	43,978	228,665	88,846
Sales and marketing, includes $0, $0, $0 and $0 in stock-based compensation	2,848	109	2,848	147
Total Operating Expenses	398,480	2,555,525	1,455,278	3,800,214
NET LOSS FROM OPERATIONS	(398,480)	(2,555,525)	(1,455,278)	(3,800,214)
OTHER INCOME (EXPENSE)
Interest expense	(448)	(448)	(902)	(1,027)
Gain on forgiveness of debt			32,500	45,000
Amortization of debt discount	(135,389)		(300,000)
Total Other Income (Expense)	(135,837)	(448)	(268,402)	43,973
Net loss before income taxes	(534,317)	(2,555,973)	(1,723,680)	(3,756,241)
Income tax provision
NET LOSS	$ (534,317)	$ (2,555,973)	$ (1,723,680)	$ (3,756,241)
Net loss per share - basic and diluted (in Dollars per share)	$ (0.14)	$ (0.67)	$ (0.44)	$ (0.98)
Weighted average number of shares outstanding during the period - basic and diluted (in Shares)	3,929,205	3,842,967	3,917,891	3,821,278

Statements of Operations (Una_2

Statements of Operations (Unaudited) (Parentheticals) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
General and Administrative Expense [Member]
Stock-based compensation	$ 160,329	$ 2,098,759	$ 689,766	$ 2,822,367
Research and Development Expense [Member]
Stock-based compensation	0	0	0	0
Selling and Marketing Expense [Member]
Stock-based compensation	$ 0	$ 0	$ 0	$ 0

Statements of Stockholders' Def

Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Shares	Treasury Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 3,764		$ 4,361,725	$ (5,902,223)	$ (1,536,734)
Balance (in Shares) at Dec. 31, 2018	3,763,925
Issuance of shares for cash, net of issuance costs	$ 60		198,594		198,654
Issuance of shares for cash, net of issuance costs (in Shares)	60,250
Issuance of shares for services	$ 13		51,987		52,000
Issuance of shares for services (in Shares)	13,000
Stock option and warrant compensation			671,608		671,608
Net loss				(1,200,268)	(1,200,268)
Balance at Mar. 31, 2019	$ 3,837		5,283,914	(7,102,491)	(1,814,740)
Balance (in Shares) at Mar. 31, 2019	3,837,175
Balance at Dec. 31, 2018	$ 3,764		4,361,725	(5,902,223)	(1,536,734)
Balance (in Shares) at Dec. 31, 2018	3,763,925
Net loss					(3,756,241)
Balance at Jun. 30, 2019	$ 3,856	(90,712)	7,419,464	(9,658,464)	(2,325,856)
Balance (in Shares) at Jun. 30, 2019	3,810,569
Balance at Mar. 31, 2019	$ 3,837		5,283,914	(7,102,491)	(1,814,740)
Balance (in Shares) at Mar. 31, 2019	3,837,175
Issuance of shares for cash, net of issuance costs	$ 11		36,799		36,810
Issuance of shares for cash, net of issuance costs (in Shares)	11,250
Stock option and warrant compensation			2,068,759		2,068,759
Issuance of shares for services and licenses	$ 8		29,992		30,000
Issuance of shares for services and licenses (in Shares)	7,500
Treasury stock		(90,712)			(90,712)
Treasury stock (in Shares)	(45,356)
Net loss				(2,555,973)	(2,555,973)
Balance at Jun. 30, 2019	$ 3,856	(90,712)	7,419,464	(9,658,464)	(2,325,856)
Balance (in Shares) at Jun. 30, 2019	3,810,569
Balance at Dec. 31, 2019	$ 3,916	(189,625)	9,063,483	(11,729,951)	(2,852,177)
Balance (in Shares) at Dec. 31, 2019	3,821,087
Issuance of shares for services	$ 105		418,895		419,000
Issuance of shares for services (in Shares)	104,750
Stock option and warrant compensation			110,437		110,437
Treasury stock		(11,980)			(11,980)
Treasury stock (in Shares)	(5,990)
Net loss				(1,189,363)	(1,189,363)
Balance at Mar. 31, 2020	$ 4,021	(201,605)	9,592,815	(12,919,314)	(3,524,083)
Balance (in Shares) at Mar. 31, 2020	3,919,847
Balance at Dec. 31, 2019	$ 3,916	(189,625)	9,063,483	(11,729,951)	(2,852,177)
Balance (in Shares) at Dec. 31, 2019	3,821,087
Net loss					(1,723,680)
Balance at Jun. 30, 2020	$ 4,069	(201,605)	9,938,946	(13,453,631)	(3,712,221)
Balance (in Shares) at Jun. 30, 2020	3,968,312
Balance at Mar. 31, 2020	$ 4,021	(201,605)	9,592,815	(12,919,314)	(3,524,083)
Balance (in Shares) at Mar. 31, 2020	3,919,847
Stock option and warrant compensation			77,138		77,138
Issuance of shares for services and licenses	$ 18		83,174		83,192
Issuance of shares for services and licenses (in Shares)	17,500
Adjustment to Common Shares due to reverse stock split	$ (1)				(1)
Adjustment to Common Shares due to reverse stock split (in Shares)	(10)
Net loss				(534,317)	(534,317)
Balance at Jun. 30, 2020	$ 4,069	(201,605)	9,938,946	(13,453,631)	(3,712,221)
Balance (in Shares) at Jun. 30, 2020	3,968,312
Exercise of warrants	$ 31		$ 185,819		$ 185,850
Exercise of warrants (in Shares)	30,975

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,723,680)	$ (3,756,241)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	689,766	2,822,367
Amortization of debt discount	300,000
Changes in operating assets and liabilities:
Prepaid expenses	(25,083)
Accounts payable and accrued expenses	95,429	365,653
Accrued compensation to related parties	257,978	256,014
Net cash used in operating activities	(405,590)	(309,207)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable - related party		10,000
Proceeds from notes payable	375,000
Repayments of notes payable - related party		(42,502)
Repayments of notes payable		(5,000)
Common stock issued for cash, net of issuance costs		235,464
Deferred offering costs	(109,425)
Exercise of warrants	185,850
Net cash provided by financing activities	451,425	197,962
NET INCREASE (DECREASE) IN CASH	45,835	(111,245)
CASH AT BEGINNING OF PERIOD	4,090	115,709
CASH AT END OF PERIOD	49,925	4,464
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest expense
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Liabilities assumed for common stock	11,980	90,712
Deferred offering costs accrued and payable	313,714
Original issuance discount on notes payable	$ 300,000

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Aditx Therapeutics, Inc. (“Aditxt” or the “Company”) was incorporated on September 28, 2017 under the laws of the State of Delaware. The Company is a pre-clinical stage, life sciences company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. Aditxt is developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system and the Company plans to utilize in its upcoming clinical trials to monitor subjects’ immune response before, during and after drug administration. Aditxt is also evaluating plans to obtain approval from the U.S. Food and Drug Administration (FDA) for this monitoring tool’s use as a clinical assay. On July 2, 2020, the Company completed its initial public offering (“IPO”). In connection therewith, the Company issued 1,226,668 Units (the “Units”), excluding the underwriters’ option to cover overallotments, at an offering price of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share of common stock, one Series A warrant, and one Series B warrant. The Series A warrants have an exercise price of $9.00 and a term of 5 years. The Series B warrants have exercise price of $11.25, a term of 5 years and contain a cashless exercise option upon certain criteria being met. Subsequent to quarter end, substantially all of the Series B warrants issued in the IPO have been exercised pursuant to a cashless provision therein. Risks and Uncertainties The Company has a limited operating history and has not generated revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations. On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raise efforts and additional development of our technologies may be negatively affected.

Going Concern Analysis

Going Concern Analysis	6 Months Ended
	Jun. 30, 2020
Going Concern Disclosure [Abstract]
GOING CONCERN ANALYSIS	NOTE 2 – GOING CONCERN ANALYSIS Management Plans The Company was incorporated on September 28, 2017 and has not generated revenues to date. During the six months ended June 30, 2020, the Company had a net loss of $1,723,680 and cash of $49,925. However, subsequent to June 30, 2020, the Company received approximately $9.5 million in cash as net proceeds from the IPO (See Note 1). The Company will be conducting medical research and development, and the time at which the Company will begin generating revenue is unknown. The Company believes, however, that the funds raised by the IPO will be sufficient to fund the Company’s operation for at least the next 12 months. Because of these factors, the Company believes that this alleviates issues in connection with the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. While we believe in the viability of our strategy to generate sufficient revenue, control costs and raise additional funds when necessary, there can be no assurances to that effect. The Company’s ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating expenses.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2020 and 2019. Although management believes that the disclosures in these unaudited financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been or omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2019, which contain the audited financial statements and notes thereto, included in the Company’s Prospectus, dated June 29, 2020, filed with the SEC pursuant to Rule 424(b). The interim results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ended December 31, 2020 or for any future interim periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates. Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2020 and December 31, 2019, the Company did not have any cash equivalents. Offering Costs The Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted against the proceeds of the offering in stockholders’ deficit or the related debt, as applicable. Costs related to unsuccessful offerings are expensed. Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. Patents The Company incurs fees from patent licenses. During the six months ended June 30, 2020 and 2019, the Company had a licensing fee for the patents of $126,670 and $15,181, respectively. Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. Our research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of June 30, 2020, 1,110,000 stock options and 1,291,503 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of June 30, 2019, 1,102,500 stock options and 1,077,173 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. Recent Accounting Pronouncements In February 2016, FASB issued Accounting Standards Update (“ASU”) 2016-02: Leases (Topic 842). The new guidance generally requires an entity to recognize on its balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The new standard requires a modified retrospective transition for existing leases to each prior reporting period presented. The Company has elected to utilize the extended adoption period available to the Company as an emerging growth company and has not currently adopted this standard. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial position, results of operations and cash flows once adopted. The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS The Company’s Chief Executive Officer (“CEO”) has provided certain periods of service without payment. As of June 30, 2020 and December 31, 2019, the CEO is owed $375,500 and $309,500, respectively, related to compensation. Subsequent to the period, the Company issued 38,055 Units consisting of 1 share of common stock and 1 Series A warrant and 1 Series B warrant to settle $342,500 in accrued compensation. The Company’s Chief Innovation Officer (“CIO”) has provided certain periods of service without payment. As of June 30, 2020 and December 31, 2019, the CIO is owed $476,000 and $377,000, respectively, related to compensation. Subsequent to the period, the Company issued 47,222 Units consisting of 1 share of common stock and 1 Series A warrant and 1 Series B warrant to settle $425,000 in accrued compensation. Effective July 10, 2020, the Board of Directors appointed the Company’s Chief Operations Officer (“COO”). Prior to the appointment, the COO was an independent operations consultant and had provided certain periods of service without payment. As of June 30, 2020 and December 31, 2019, the COO is owed $365,000 and $275,000, respectively, related to compensation. Subsequent to the period, the Company issued 35,555 Units consisting of 1 share of common stock, 1 Series A warrant, and 1 Series B warrant to settle $320,000 in accrued compensation. On March 21, 2019, the Company entered into a note with a related party. The note had a principal of $10,000, a maturity date of September 21, 2019, and an interest rate of 4% per year. The note remained outstanding on June 30, 2020. This note was paid in full subsequent to June 30, 2020. During the six months ended June 30, 2020, the Company assumed $11,980 of liabilities from a related party in exchange for the return of 5,990 shares of the Company’s common stock.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 5 – STOCKHOLDERS’ DEFICIT Preferred Stock The Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share. Common Stock The Company is authorized to issue 27,000,000 shares of common stock, par value $0.001 per share. During the six months ended June 30, 2020, the Company issued 122,250 shares of common stock and recognized expense of $502,192 in stock compensation for consulting services. The Company also issued 30,975 shares of commons stock for the exercise of warrants and received $185,850 for the exercise of the warrants. The compensation was valued based on prior private placements or based on management’s estimates of value immediately prior to the IPO. During six months ended June 30, 2019, the Company issued 20,500 shares of common stock for services and recognized expense of $82,000 in stock compensation, issued 71,500 shares of common stock for $235,464 in cash, net of offering costs, and received 45,356 shares of the Company’s common stock in exchange for the assumption of $90,712 in liabilities. Shares issued for compensation were valued based on the price which common shares were being sold in the above private placements. Reverse Stock Split On June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split. Stock-Based Compensation In October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of equity awards to employees, and consultants. Up to 2,500,000 shares of our common stock may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after adoption, unless terminated earlier by the Board. During the six months ended June 30, 2020, the Company granted 7,500 stock options to a related party with exercise prices of $11.00 per share vesting on issuance. The total grant date fair value was determined to be $27,799. During the six months ended June 30, 2019, the Company granted 550,000 stock options with exercise prices of $4.00 per share vesting on issuance. The total grant date fair value was determined to be $1,960,831. For all periods presented, the fair value of each stock option granted was estimated using the Black-Scholes assumption ranges and or factors as follows: Exercise price $ 4.00-11.00 Expected dividend yield 0 % Risk free interest rate 0.39% - 2.65 % Expected life in years 2.79-7.52 Expected volatility 141-146 % The risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities appropriate for the expected term of stock options. The expected term of stock options is calculated using either the simplified method for employee options which takes into consideration the contractual life and vesting terms of the options, unless the options are expected to vest in which case the contractual term of the options. The Company determined the expected volatility assumption for options granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future stock option grants, until such time that the Company’s common stock has enough market history to use historical volatility. The dividend yield assumption for options granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. Management estimated the fair value of common stock by looking at a market approach which takes into consideration past sales of stock to third parties and Company developments to date. The Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates. The following is an analysis of the stock option grant activity under the Plan: Weighted Weighted Number Exercise Remaining Stock Options Outstanding December 31, 2019 1,102,500 $ 4.00 7.77 Granted 7,500 11.00 7.52 Expired or forfeited - - - Outstanding June 30, 2020 (unaudited) 1,110,000 $ 4.05 7.25 Nonvested Options Shares Weighted- Nonvested at December 31, 2019 - $ - Granted 7,500 11.00 Vested (7,500 ) 11.00 Forfeited - - Nonvested at June 30, 2020 (unaudited) - $ - The Company recognized compensation expense related to options issued and vesting of $27,799 during the six months ended June 30, 2020, which is included in general and administrative expenses in the accompanying statements of operations. There is no additional expense to be recognized on previously granted options as of June 30, 2020. The Company recognized compensation expense related to options issued and vesting of $2,513,826 during the period ended June 30, 2019, which is included in general and administrative expenses in the accompanying statements of operations. Warrants A summary of warrant issuances are as follows: Number Weighted Weighted Warrants Outstanding December 31, 2019 1,382,478 4.44 2.84 Granted 5,000 11.00 3.00 Forfeited (65,000 ) 4.00 - Exercised (30,975 ) 6.00 - Outstanding June 30, 2020 (unaudited) 1,291,503 $ 4.46 2.32 Nonvested Warrants Shares Weighted- Nonvested at December 31, 2019 200,000 4.00 Granted 5,000 - Vested - - Forfeited (65,000 ) - Nonvested at June 30, 2020 (unaudited) 140,000 $ 4.00 The warrants are valued using similar inputs as noted in the stock options section above, with the exception of the expected life which is the contractual life. The Company recognized compensation expense related to warrants issued and vesting of $159,777 and $226,541 during the six months ended June 30, 2020 and 2019, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to be expensed is $212,093 with a weighted average vesting term of 0.97 years as of June 30, 2020. During the six months ended June 30, 2020, 30,975 warrants were exercised for 30,975 shares of common stock. The Company recognized proceeds of $185,850 related to the exercises. During the three months ended June 30, 2020, the Company issued 5,000 warrants with an exercise price of $11.00 and a term of 3 years. On April 10, 2020, the Company terminated a consulting agreement dated December 1, 2018. As part of this termination agreement the consultant forfeited 65,000 non-vested. The consultant holds 25,000 warrants which were previously vested.

Agreements

Agreements	6 Months Ended
	Jun. 30, 2020
Agreements Disclosure [Abstract]
AGREEMENTS	NOTE 6 – AGREEMENTS On December 27, 2019, the Company entered into a consulting agreement for advisory services that requires a monthly retainer payment of $2,000. The Company issued 10,000 shares of its common stock during January 2020. Additionally, the Company issued 15,000 shares of its common stock within ten business days of the Company’s IPO and will issue 15,000 shares of its common stock within ten business days of December 31, 2020. On December 27, 2019, the Company entered into a consulting agreement for advisory services. As part of this agreement the Company paid a one-time retainer of $15,000. Additionally, the Company paid a $7,500 success fee and issued 5,000 shares of its common stock within ten business days of the Company’s IPO. On January 9, 2020, the Company entered into a consulting agreement for advisory services that requires a monthly retainer payment of $4,000. In addition, the Company issued 10,000 shares of its common stock during January 2020. Additionally, the Company issued 15,000 shares of its commons stock in June 2020 and will be required to issue 15,000 shares of its common stock within ten business days after December 17, 2020. On January 10, 2020, the Company entered into a consulting agreement for advisory services, which was amended in May 2020. As part of this agreement the Company issued 55,000 shares of its common stock during January 2020. Additionally, the Company issued 55,000 shares of its common stock within ten business days of the Company’s IPO. On January 22, 2020, as amended, effective July 1, 2020, the Company entered into a consulting agreement for investor relations and capital market advisory services. As part of this agreement the Company will pay a fee of $12,000 per month and issue 30,000 shares of the Company’s common stock. On February 3, 2020, the Company entered into a patent licensing agreement. As part of this agreement the Company is required to pay a fee of $25,000. The Company also issued 18,750 shares of the Company’s common stock to the patent holder. The Company is required to pay an annual licensing fee on the anniversary of the agreement in the amount of $40,000 for 2021 through 2024 and $60,000 in starting in 2025 until the license expires. The Company will also pay milestone fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in vitro diagnostic product developed and a potential licensed product. The Company will be responsible for paying royalty fees on the Company’s net sales. These royalty fees are set at a rate of 4% when net sales are below or equal to $5 million annually or 6% when net sales are above $5 million annually. On February 23, 2020, the Company entered into a consulting agreement for business development services. As part of this agreement the Company issued 5,000 shares of its common stock. The Company also issued an additional 3,000 shares of its common stock upon the completion of its IPO. Subsequent to the IPO the Company will pay a monthly fee of $8,000. The Company will also pay a success fee equal to 4% of transaction proceeds in connection with qualified transactions. On March 30, 2020, the Company entered into an employment agreement for a permanent, full-time Chief Financial Officer that is effective upon the closing of the Company’s IPO. As part of the employment agreement the Company agreed to pay the employee $225,000 per year. The Company also granted stock options to purchase shares of the Company’s common stock. An initial grant of 7,500 options was made upon the signing of the agreement and a subsequent grant of 165,000 options was made upon the completion of the IPO. The initial grant has an exercise price of $11.00 and expires on October 5, 2027, the subsequent grant was issued at the IPO price. The initial grant vested immediately and the subsequent grant vests 1/3 on the first anniversary of the agreement and the remaining 2/3 vests quarterly over the next two years. On April 30, 2020, the Company entered into an employment agreement for a Vice President of Preclinical Research and Development that is effective upon the closing of the Company’s IPO. As part of the employment agreement, the Company agreed to pay the employee $200,000 per year. The Company granted 90,000 stock options to purchase shares of the Company’s common stock upon the completion of the IPO. The initial grant has an exercise price of equal to that of the IPO and expires on October 5, 2027. The grant vests 1/3 on the first anniversary of the start date of the employee and the remaining 2/3 vests quarterly over the following two years starting on the end of the 15 th On May 16, 2020, the Company entered into an employment agreement for a Vice President of Innovation Portfolio and Development that is effective upon the closing of the Company’s IPO. As part of the employment agreement, the Company agreed to pay the employee $200,000 per year. The Company granted 90,000 stock options to purchase shares of the Company’s common stock upon the completion of the IPO. The initial grant has an exercise price of equal to that of the IPO and expires on October 5, 2027. The grant vests 1/3 on the first anniversary of the start date of the employee and the remaining 2/3 vests quarterly over the following two years starting on the end of the 15 th On June 15, 2020 the Company entered into a consulting agreement for advisory services that required a fee equivalent to 3,000 shares of the Company’s common stock which were issued in July 2020.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE On April 12, 2018, the Company issued an unsecured promissory note for $35,000 that accrued interest of 4% annually. The note was due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020. On July 10, 2018, the Company entered into a bridge loan with a principal of $15,600. The note was due on the earlier of October 8, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020. On July 18, 2018, the Company entered into a bridge loan with a principal of $130,000. The note was due on the earlier of October 16, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020. On November 1, 2019, the Company entered into a bridge loan with a principal of $50,000. This loan did not accrue any interest. The note was due on the earlier of April 28, 2020 or in the event of default, as defined in the agreement. The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00 per share. On July 24, 2020, the Company entered into an exchange agreement with respect to the previously issued note to exchange the note into Units on the same terms as the securities offered by the Company in its IPO. The note was converted in full subsequent to June 30, 2020. On January 10, 2020, the Company entered into a bridge loan with a principal amount of $75,000. This Note carried an original issue discount of $40,000. This loan did not accrue any interest. The note was due on the earlier of July 8, 2020 or in the event of default, as defined in the agreement, as amended. The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00 per share. The note was converted in full subsequent to June 30, 2020. During the first quarter of 2020, the Company entered into six bridge loans with a total principal amount of $600,000. These notes carried a total original issue discount of $300,000. The notes were due on the earlier of April 19, 2020 or ten days after the close of the Company’s IPO. These notes were paid in full subsequent to June 30, 2020.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS On July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (“LLU”), dated March 15, 2018. Pursuant to the amendment, the Company was to pay LLU $455,000 within four days of the signing of such amendment. The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027. Effective on July 1, 2020, the Company entered into a consulting agreement for investor relations and public relations services. As part of this agreement the Company will pay a fee of $8,000 per month and issue 20,000 shares of the Company’s common stock. On July 2, 2020, the Company completed its IPO. (See Note 1). On July 2, 2020, the Company settled outstanding compensation with certain related parties. (See Note 4). See Note 6 for descriptions of agreements that required shares to be issued or options to be granted upon completion of the Company’s IPO. Such shares have been issued and options granted. Subsequent to June 30, 2020, the Company repaid or exchanged for shares all debt agreements described in Note 8.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2020 and 2019. Although management believes that the disclosures in these unaudited financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been or omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2019, which contain the audited financial statements and notes thereto, included in the Company’s Prospectus, dated June 29, 2020, filed with the SEC pursuant to Rule 424(b). The interim results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ended December 31, 2020 or for any future interim periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.
Fair Value Measurements and Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2020 and December 31, 2019, the Company did not have any cash equivalents.
Offering Costs	Offering Costs The Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted against the proceeds of the offering in stockholders’ deficit or the related debt, as applicable. Costs related to unsuccessful offerings are expensed.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services.
Patents	Patents The Company incurs fees from patent licenses. During the six months ended June 30, 2020 and 2019, the Company had a licensing fee for the patents of $126,670 and $15,181, respectively.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. Our research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of June 30, 2020, 1,110,000 stock options and 1,291,503 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of June 30, 2019, 1,102,500 stock options and 1,077,173 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, FASB issued Accounting Standards Update (“ASU”) 2016-02: Leases (Topic 842). The new guidance generally requires an entity to recognize on its balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The new standard requires a modified retrospective transition for existing leases to each prior reporting period presented. The Company has elected to utilize the extended adoption period available to the Company as an emerging growth company and has not currently adopted this standard. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial position, results of operations and cash flows once adopted. The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2020
Stockholders' Equity Note [Abstract]
Schedule of stock option granted was estimated using the Black-Scholes assumption	Exercise price $ 4.00-11.00 Expected dividend yield 0 % Risk free interest rate 0.39% - 2.65 % Expected life in years 2.79-7.52 Expected volatility 141-146 %
Schedule of analysis of the stock option grant activity under the plan	Weighted Weighted Number Exercise Remaining Stock Options Outstanding December 31, 2019 1,102,500 $ 4.00 7.77 Granted 7,500 11.00 7.52 Expired or forfeited - - - Outstanding June 30, 2020 (unaudited) 1,110,000 $ 4.05 7.25 Number Weighted Weighted Warrants Outstanding December 31, 2019 1,382,478 4.44 2.84 Granted 5,000 11.00 3.00 Forfeited (65,000 ) 4.00 - Exercised (30,975 ) 6.00 - Outstanding June 30, 2020 (unaudited) 1,291,503 $ 4.46 2.32
Schedule of nonvested option	Nonvested Options Shares Weighted- Nonvested at December 31, 2019 - $ - Granted 7,500 11.00 Vested (7,500 ) 11.00 Forfeited - - Nonvested at June 30, 2020 (unaudited) - $ - Nonvested Warrants Shares Weighted- Nonvested at December 31, 2019 200,000 4.00 Granted 5,000 - Vested - - Forfeited (65,000 ) - Nonvested at June 30, 2020 (unaudited) 140,000 $ 4.00

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - IPO [Member] - Subsequent Event [Member]	Jul. 02, 2020$ / sharesshares
Organization and Nature of Business (Details) [Line Items]
Company issued (in Shares) | shares	1,226,668
Company issued per unit	$ 9
Total offering price (in Shares) | shares	11,000,000
Series A warrant [Member]
Organization and Nature of Business (Details) [Line Items]
Exercise price	$ 9
Exercise price term	5 years
Series B warrant [Member]
Organization and Nature of Business (Details) [Line Items]
Exercise price	$ 11.25
Exercise price term	5 years

Going Concern Analysis (Details

Going Concern Analysis (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Going Concern Disclosure [Abstract]
Net loss	$ (534,317)	$ (1,189,363)	$ (2,555,973)	$ (1,200,268)	$ (1,723,680)	$ (3,756,241)
Cash of net income					49,925
proceeds from IPO					$ 9,500,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Licensing fees (in Dollars)	$ 126,670	$ 15,181
Warrants of stock option	1,110,000	1,102,500
Dilutive earnings share	1,291,503	1,077,173

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended		6 Months Ended
	Jan. 22, 2020	Mar. 21, 2019	Jun. 30, 2020	Dec. 31, 2019
Related Party Transactions (Details) [Line Items]
Accrued compensation			$ 342,500
Principal amount		$ 10,000
Interest rate		4.00%
Description of note	As part of this agreement the Company will pay a fee of $12,000 per month and issue 30,000 shares of the Company’s common stock.	This note was paid in full subsequent to June 30, 2020.
Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Amount of liabilities from related party			$ 11,980
Shares of liabilities from related party (in Shares)			5,990
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Owed amount of related party			$ 375,500	$ 309,500
Description of related party transactions			Subsequent to the period, the Company issued 38,055 Units consisting of 1 share of common stock and 1 Series A warrant and 1 Series B warrant to settle $342,500 in accrued compensation.
Chief Innovation Officer [Member]
Related Party Transactions (Details) [Line Items]
Owed amount of related party			$ 476,000	377,000
Description of related party transactions			Subsequent to the period, the Company issued 47,222 Units consisting of 1 share of common stock and 1 Series A warrant and 1 Series B warrant to settle $425,000 in accrued compensation.
Accrued compensation			$ 425,000
Chief Operating Officer [Member]
Related Party Transactions (Details) [Line Items]
Owed amount of related party			$ 365,000	$ 275,000
Description of related party transactions			Subsequent to the period, the Company issued 35,555 Units consisting of 1 share of common stock, 1 Series A warrant, and 1 Series B warrant to settle $320,000 in accrued compensation.
Accrued compensation			$ 320,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)	Apr. 10, 2020	Jun. 29, 2020	Oct. 31, 2017	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stockholders' Deficit (Details) [Line Items]
Preferred stock, shares authorized (in Shares)				3,000,000	3,000,000		3,000,000
Preferred stock, par value (in Dollars per share)				$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized (in Shares)				27,000,000	27,000,000		27,000,000
Common stock, par value (in Dollars per share)				$ 0.001	$ 0.001		$ 0.001
Common stock issued (in Shares)				122,250	122,250
Services and recognized expense					$ 502,192	$ 82,000
Sale of common stock (in Shares)					30,975	71,500
Exercise of warrants and received					$ 185,850
Common stock issued (in Shares)				4,069,115	4,069,115	20,500	3,915,900
Cash received						$ 235,464
Offering costs shares (in Shares)						45,356
assumption of common stock liabilities						$ 90,712
Reverse stock split, description		On June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware.
Compensation expense related to options issued and vesting					$ 27,799	2,513,826
Warrants issued and vesting					159,777	$ 226,541
General and administrative expenses					$ 212,093
Weighted average vesting term					354 days
Warrants were exercised					$ 30,975
Proceeds from exercised					$ 185,850
Company issued warrants with an exercise				$ 5,000
Proceeds from exercised per share (in Dollars per share)				$ 11
Company issued warrants with an exercise term				3 years
Warrant vested price (in Dollars per share)	$ 25,000
Stock option [member]
Stockholders' Deficit (Details) [Line Items]
Company granted (in Shares)					7,500	550,000
Exercise prices (in Dollars per share)					$ 11	$ 4
Total grant fair value					$ 27,799	$ 1,960,831
Nonvested Warrants [Member]
Stockholders' Deficit (Details) [Line Items]
Shares forfeited (in Shares)					65,000
Warrant [Member] | Nonvested Warrants [Member]
Stockholders' Deficit (Details) [Line Items]
Shares forfeited (in Shares)	65,000
2017 Equity Incentive Plan [Member]
Stockholders' Deficit (Details) [Line Items]
Share issued for stock based compensation (in Shares)			2,500,000

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Stock option granted was estimated using the Black-Scholes assumption	6 Months Ended
	Jun. 30, 2020$ / shares
Stockholders' Deficit (Details) - Stock option granted was estimated using the Black-Scholes assumption [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Stockholders' Deficit (Details) - Stock option granted was estimated using the Black-Scholes assumption [Line Items]
Exercise price (in Dollars per share)	$ 4
Risk free interest rate	0.39%
Expected life in years	2 years 288 days
Expected volatility	141.00%
Maximum [Member]
Stockholders' Deficit (Details) - Stock option granted was estimated using the Black-Scholes assumption [Line Items]
Exercise price (in Dollars per share)	$ 11
Risk free interest rate	2.65%
Expected life in years	7 years 189 days
Expected volatility	146.00%

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of analysis of the stock option grant activity under the plan	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Stock Options [Member]
Stock Options
Number, Outstanding beginning balance | shares	1,102,500
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 4
Weighted Average Remaining Life, Outstanding beginning balance	7 years 281 days
Number, Granted | shares	7,500
Weighted Average Exercise Price, Granted | $ / shares	$ 11
Weighted Average Remaining Life, Granted	7 years 189 days
Number, Expired or forfeited | shares
Weighted Average Exercise Price, Expired or forfeited | $ / shares
Number, Outstanding ending balance | shares	1,110,000
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 4.05
Weighted Average Remaining Life, Outstanding ending balance	7 years 3 months
Warrants [Member]
Stock Options
Number, Outstanding beginning balance | shares	1,382,478
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 4.44
Weighted Average Remaining Life, Outstanding beginning balance	2 years 306 days
Number, Granted | shares	5,000
Weighted Average Exercise Price, Granted | $ / shares	$ 11
Weighted Average Remaining Life, Granted	3 years
Number, Expired or forfeited | shares	(65,000)
Weighted Average Exercise Price, Expired or forfeited | $ / shares	$ 4
Number, Exercised | shares	(30,975)
Weighted Average Exercise Price, Exercised | $ / shares	$ 6
Number, Outstanding ending balance | shares	1,291,503
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 4.46
Weighted Average Remaining Life, Outstanding ending balance	2 years 116 days

Stockholders' Deficit (Detail_4

Stockholders' Deficit (Details) - Schedule of nonvested option	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Nonvested Warrants [Member]
Stockholders' Deficit (Details) - Schedule of nonvested option [Line Items]
Shares, Nonvested at beginning balance	200,000
Weighted- Average Exercise Price, Outstanding beginning balance (in Dollars per share) | $ / shares	$ 4
Shares, Granted	5,000
Weighted- Average Exercise Price, Granted (in Dollars per share) | $ / shares
Shares, Vested
Weighted- Average Exercise Price, Vested
Shares, Forfeited	(65,000)
Weighted- Average Exercise Price, Forfeited (in Dollars per share) | $ / shares
Shares, Nonvested at ending balance	140,000
Weighted- Average Exercise Price, Outstanding ending balance (in Dollars per share) | $ / shares	$ 4
Nonvested Options [Member]
Stockholders' Deficit (Details) - Schedule of nonvested option [Line Items]
Shares, Nonvested at beginning balance
Weighted- Average Exercise Price, Outstanding beginning balance (in Dollars per share) | $ / shares
Shares, Granted	7,500
Weighted- Average Exercise Price, Granted (in Dollars per share) | $ / shares	$ 11
Shares, Vested	(7,500)
Weighted- Average Exercise Price, Vested	11
Shares, Forfeited
Weighted- Average Exercise Price, Forfeited (in Dollars per share) | $ / shares
Shares, Nonvested at ending balance
Weighted- Average Exercise Price, Outstanding ending balance (in Dollars per share) | $ / shares

Agreements (Details)

Agreements (Details)	Jan. 10, 2020	Jan. 09, 2020	Dec. 27, 2019	May 16, 2020	Mar. 30, 2020	Feb. 23, 2020	Feb. 03, 2020	Jan. 22, 2020	Mar. 21, 2019
Agreements (Details) [Line Items]
Description of agreement								As part of this agreement the Company will pay a fee of $12,000 per month and issue 30,000 shares of the Company’s common stock.	This note was paid in full subsequent to June 30, 2020.
Employment agreement, description				As part of the employment agreement, the Company agreed to pay the employee $200,000 per year. The Company granted 90,000 stock options to purchase shares of the Company’s common stock upon the completion of the IPO. The initial grant has an exercise price of equal to that of the IPO and expires on October 5, 2027. The grant vests 1/3 on the first anniversary of the start date of the employee and the remaining 2/3 vests quarterly over the following two years starting on the end of the 15th month following the start date.
Consulting agreement [Member]
Agreements (Details) [Line Items]
Description of agreement	As part of this agreement the Company issued 55,000 shares of its common stock during January 2020. Additionally, the Company issued 55,000 shares of its common stock within ten business days of the Company’s IPO.	the Company entered into a consulting agreement for advisory services that requires a monthly retainer payment of $4,000. In addition, the Company issued 10,000 shares of its common stock during January 2020. Additionally, the Company issued 15,000 shares of its commons stock in June 2020 and will be required to issue 15,000 shares of its common stock within ten business days after December 17, 2020.	the Company entered into a consulting agreement for advisory services that requires a monthly retainer payment of $2,000. The Company issued 10,000 shares of its common stock during January 2020. Additionally, the Company issued 15,000 shares of its common stock within ten business days of the Company’s IPO and will issue 15,000 shares of its common stock within ten business days of December 31, 2020.
Stockholders equity, description						the Company entered into a consulting agreement for business development services. As part of this agreement the Company issued 5,000 shares of its common stock. The Company also issued an additional 3,000 shares of its common stock upon the completion of its IPO. Subsequent to the IPO the Company will pay a monthly fee of $8,000. The Company will also pay a success fee equal to 4% of transaction proceeds in connection with qualified transactions.
Consulting Agreement [Member]
Agreements (Details) [Line Items]
Description of agreement			As part of this agreement the Company paid a one-time retainer of $15,000. Additionally, the Company paid a $7,500 success fee and issued 5,000 shares of its common stock within ten business days of the Company’s IPO.
Patent licensing agreement [Member]
Agreements (Details) [Line Items]
Stockholders equity, description							The Company also issued 18,750 shares of the Company’s common stock to the patent holder. The Company is required to pay an annual licensing fee on the anniversary of the agreement in the amount of $40,000 for 2021 through 2024 and $60,000 in starting in 2025 until the license expires. The Company will also pay milestone fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in vitro diagnostic product developed and a potential licensed product. The Company will be responsible for paying royalty fees on the Company’s net sales. These royalty fees are set at a rate of 4% when net sales are below or equal to $5 million annually or 6% when net sales are above $5 million annually.
Employment agreement [Member]
Agreements (Details) [Line Items]
Stockholders equity, description					As part of the employment agreement the Company agreed to pay the employee $225,000 per year. The Company also granted stock options to purchase shares of the Company’s common stock. An initial grant of 7,500 options was made upon the signing of the agreement and a subsequent grant of 165,000 options was made upon the completion of the IPO. The initial grant has an exercise price of $11.00 and expires on October 5, 2027, the subsequent grant was issued at the IPO price. The initial grant vested immediately and the subsequent grant vests 1/3 on the first anniversary of the agreement and the remaining 2/3 vests quarterly over the next two years.

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Apr. 25, 2020	Jul. 10, 2018	Jul. 18, 2018	Mar. 31, 2020	Jan. 10, 2020	Nov. 01, 2019	Apr. 12, 2018
Notes Payable (Details) [Line Items]
Unsecured promissory note							$ 35,000
Accrued interest rate							4.00%
Maturity date, description	The notes were due on the earlier of April 19, 2020 or ten days after the close of the Company’s IPO.
Seven bridge loans [Member]
Notes Payable (Details) [Line Items]
Original issue discount				$ 300,000
Total principal amount				$ 600,000
Bridge Loan [Member]
Notes Payable (Details) [Line Items]
Bridge loan, description		The note was due on the earlier of October 8, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020. On July 18, 2018, the Company entered into a bridge loan with a principal of $130,000. The note was due on the earlier of October 16, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020.	The note was due on the earlier of October 16, 2018 or in the event of default, as defined in the agreement. This note was paid in full subsequent to June 30, 2020.
Principal amount					$ 75,000	$ 50,000
Conversion price (in Dollars per share)					$ 2	$ 2
Original issue discount					$ 40,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Jul. 01, 2020USD ($)	Jul. 01, 2020USD ($)shares
Subsequent Events (Details) [Line Items]
Subsequent event, description	the Company was to pay LLU $455,000 within four days of the signing of such amendment. The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027.
Fee pay | $	$ 8,000	$ 8,000
Common stock shares issue | shares		20,000